-
1
-
-
46849088805
-
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005
-
Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 960-966
-
-
Annemans, L.1
Spaepen, E.2
Gaskin, M.3
Bonnemaire, M.4
Malier, V.5
Gilbert, T.6
-
3
-
-
70449721119
-
Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007
-
Elliot A.J., Cross K.W., Fleming D.M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 2009, 68:1728-1733.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1728-1733
-
-
Elliot, A.J.1
Cross, K.W.2
Fleming, D.M.3
-
4
-
-
85172827499
-
-
Office of national statistics. National population projections, 〈〉 2012 [accessed May 2013].
-
Office of national statistics. National population projections, 〈〉 2012 [accessed May 2013]. http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2010-based-reference-volume--series-pp2/results.html%23tab-Age-structure.
-
-
-
-
5
-
-
33748608331
-
EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)
-
Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1312-1324
-
-
Zhang, W.1
Doherty, M.2
Bardin, T.3
Pascual, E.4
Barskova, V.5
Conaghan, P.6
-
6
-
-
84869186940
-
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
-
Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64:1431-1446.
-
(2012)
Arthritis Care Res
, vol.64
, pp. 1431-1446
-
-
Khanna, D.1
Fitzgerald, J.D.2
Khanna, P.P.3
Bae, S.4
Singh, M.K.5
Neogi, T.6
-
7
-
-
13344281990
-
Gout epidemiology: results from the UK general practice research database, 1990-1999
-
Mikuls T.R., Farrar J.T., Bilker W.B., Fernandes S., Schumacher H.R., Saag K.G. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005, 64:267-272.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 267-272
-
-
Mikuls, T.R.1
Farrar, J.T.2
Bilker, W.B.3
Fernandes, S.4
Schumacher, H.R.5
Saag, K.G.6
-
8
-
-
34848884310
-
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations
-
Roddy E., Zhang W.Y., Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66:1311-1315.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1311-1315
-
-
Roddy, E.1
Zhang, W.Y.2
Doherty, M.3
-
9
-
-
85172829853
-
Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system
-
Rashid N., Cheetham T.C., Curtis J.R., Levy G.D., Saag K.G., Mikuls T.R. Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system. Arthritis Rheum 2011, 63:S349.
-
(2011)
Arthritis Rheum
, vol.63
-
-
Rashid, N.1
Cheetham, T.C.2
Curtis, J.R.3
Levy, G.D.4
Saag, K.G.5
Mikuls, T.R.6
-
10
-
-
0036260510
-
Improving the quality of care of musculoskeletal conditions in primary care
-
Roberts C., Adebajo A.O., Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology 2002, 41:503-508.
-
(2002)
Rheumatology
, vol.41
, pp. 503-508
-
-
Roberts, C.1
Adebajo, A.O.2
Long, S.3
-
11
-
-
56049101851
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial
-
Schumacher H.R., Becker M.A., Wortmann R.L., MacDonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthrit Care Res 2008, 59:1540-1548.
-
(2008)
Arthrit Care Res
, vol.59
, pp. 1540-1548
-
-
Schumacher, H.R.1
Becker, M.A.2
Wortmann, R.L.3
MacDonald, P.A.4
Hunt, B.5
Streit, J.6
-
12
-
-
28944437578
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
-
Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
-
(2005)
N Engl J Med
, vol.353
, pp. 2450-2461
-
-
Becker, M.A.1
Schumacher, H.R.2
Wortmann, R.L.3
MacDonald, P.A.4
Eustace, D.5
Palo, W.A.6
-
13
-
-
35448936489
-
British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout
-
Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J.R., et al. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology 2007, 46:1372-1374.
-
(2007)
Rheumatology
, vol.46
, pp. 1372-1374
-
-
Jordan, K.M.1
Cameron, J.S.2
Snaith, M.3
Zhang, W.4
Doherty, M.5
Seckl, J.R.6
-
14
-
-
84867404142
-
Gout: why is this curable disease so seldom cured?
-
Doherty M., Jansen T.L., Nuki G., Pascual E., Perez-Ruiz F., Punzi L., et al. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis 2012, 71:1765-1770.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1765-1770
-
-
Doherty, M.1
Jansen, T.L.2
Nuki, G.3
Pascual, E.4
Perez-Ruiz, F.5
Punzi, L.6
-
15
-
-
84877586862
-
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study
-
Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013, 72:826-830.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 826-830
-
-
Rees, F.1
Jenkins, W.2
Doherty, M.3
-
16
-
-
0034088994
-
How is gout managed in primary care? A review of current practice and proposed guidelines
-
Pal B., Foxall M., Dysart T., Carey F., Whittaker M. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21-25.
-
(2000)
Clin Rheumatol
, vol.19
, pp. 21-25
-
-
Pal, B.1
Foxall, M.2
Dysart, T.3
Carey, F.4
Whittaker, M.5
-
17
-
-
84864486646
-
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
-
Stamp L.K., Taylor W.J., Jones P.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012, 64:2529-2536.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2529-2536
-
-
Stamp, L.K.1
Taylor, W.J.2
Jones, P.B.3
Dockerty, J.L.4
Drake, J.5
Frampton, C.6
-
18
-
-
85172829285
-
-
Datapharm. Electronic Medicines Compendium, 〈〉 2013 [accessed May 2013].
-
Datapharm. Electronic Medicines Compendium, 〈〉 2013 [accessed May 2013]. http://www.medicines.org.uk/emc/medicine/23722/SPC.
-
-
-
-
19
-
-
84905219493
-
Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol
-
Stamp L.K., Taylor W., Jones P.B.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol. Arthritis Rheum 2012, 63:S1012.
-
(2012)
Arthritis Rheum
, vol.63
-
-
Stamp, L.K.1
Taylor, W.2
Jones, P.B.B.3
Dockerty, J.L.4
Drake, J.5
Frampton, C.6
-
20
-
-
80155198743
-
HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency
-
Jung J.W., Song W.J., Kim Y.S., Joo K.W., Lee K.W., Kim S.H., et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011, 26:3567-3572.
-
(2011)
Nephrol Dial Transplant
, vol.26
, pp. 3567-3572
-
-
Jung, J.W.1
Song, W.J.2
Kim, Y.S.3
Joo, K.W.4
Lee, K.W.5
Kim, S.H.6
-
21
-
-
0021366307
-
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency
-
Hande K., Noone R., Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
-
(1984)
Am J Med
, vol.76
, pp. 47-56
-
-
Hande, K.1
Noone, R.2
Stone, W.3
|